Epigenetic targets in cancer epidemiology

Methods in Molecular Biology

Volumn 471, Issue , 2009, Pages 457-467

  Dumitrescu, Ramona G ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Chromatin modifications; DNA hypermethylation; DNA hypomethylation; Environment and cancer susceptibility

Indexed keywords

CHROMATIN; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW;

CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 60349083117     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-416-2_23     Document Type: Review

References (74)

1. Baylin, S.B. and Ohm, J.E. (2006) Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107-116.
2. Jacinto, F.V. and Esteller, M. (2007) Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 22, 247-253
3. Jones, P.A. and Baylin, S.B. (2007) The epigenomics of cancer. Cell 128, 683-692
4. Esteller, M. (2005) Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 45, 629-656.
5. Greger, V. et al. (1989) Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet. 83, 155-158.
6. Feinberg, A.P. (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447, 433-440.
7. Verma, M. and Manne, U. (2006) Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev. Oncol. Hematol. 60, 9-18.
8. Kawamoto, K. et al. (2006) p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem. Biophys. Res. Commun. 339, 790-796.
9. Urakami, S. et al. (2006) Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin. Cancer Res. 12, 6989-6997.
10. Friedrich, M.G. et al. (2007) DNA methylation on urinalysis and as a prognostic marker in urothelial cancer of the bladder. Urologe A 46, 761-768.
11. Yates, D.R. et al. (2007) Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 13, 2046-2053.
12. Yu, J. et al. (2004) Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4, 65.
13. Watanabe, T. et al. (2007) Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol. 17, 5-10.
14. Jiang, Z. et al. (2006) Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci. Res. 56, 450-458.
15. Lindsey, J.C. et al. (2005) Epigenetic events in medulloblastoma development. Neurosurg. Focus 19, E10.
16. Martinez-Glez, V. et al. (2007) DAPK1 promoter hypermethylaiton in brain metastases and peripheral blood. Neoplasma 54, 123-126.
17. Kim, T.Y. et al. (2006) Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 66, 7490-7501.
18. Gomori, E. et al. (2007) Epigenetic inactivation of the hMLH1 gene in progression of gliomas. Diagn. Mol. Pathol. 16, 104-107.
19. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100, 57-70.
20. Widschwendter, M. and Jones, P.A. (2002) DNA methylation and breast carcinogenesis. Oncogene 21, 5462-5482.
21. Muller, H.M. et al. (2004) Prognostic DNA methylation marker in serum of cancer patients. Ann. N Y Acad. Sci. 1022, 44-49.
22. Taback, B. et al. (2006) Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann. N Y Acad. Sci. 1075, 211-221.
23. Zhang, J.J. et al. (2007) [Detection and significance of APC gene promoter hypermethylation in serum of breast cancer patients]. Ai. Zheng 26, 44-47.
24. Jing, F. et al. (2007) Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie 30, 14-19.
25. Sharma, G. et al. (2007) Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci. 80, 1873-1881.
26. Holst, C.R. et al. (2003) Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63, 1596-1601.
27. Turan, T. et al. (2006) Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression? Virology 349, 175-183.
28. Yang, H.J. et al. (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6, 212.
29. Widschwendter, A. et al. (2004) DNA methylation in serum and tumors of cervical cancer patients. Clin. Cancer Res. 10, 565-571.
30. Kitkumthorn, N. et al. (2006) Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer. BMC Cancer 6, 55.
31. Jo, H. et al. (2007) Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer. J. Obstet. Gynaecol. Res. 33, 236-241.
32. Wallner, M. et al. (2006) Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin. Cancer Res. 12, 7347-7352.
33. Niv, Y. (2007) Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. World J. Gastroenterol. 13, 1767-1769.
34. Huang, Z. et al. (2007) Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig. Dis. Sci. 52, 2287-2291.
35. Mittag, F. et al. (2006) DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett. 240, 69-75.
36. Grote, H.J. et al. (2006) Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 108, 129-134.
37. Machida, E.O. et al. (2006) Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res. 66, 6210-6218.
38. Ulivi, P. et al. (2006) p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J. Cell Physiol 206, 611-615.
39. Belinsky, S.A. et al. (2006) Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 66, 3338-3344.
40. Li, L.C. (2007) Epigenetics of prostate cancer. Front Biosci. 12, 3377-3397.
41. Vanaja, D.K. et al. (2006) PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin. Cancer Res. 12, 1128-1136.
42. Jeronimo, C. et al. (2004) Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin. Cancer Res. 10, 4010-4014.
43. Rosenbaum, E. et al. (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res. 11, 8321-8325.
44. Henrique, R. and Jeronimo, C. (2004) Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur. Urol. 46, 660-669.
45. Bastian, P.J. et al. (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 11, 4037-4043.
46. Reibenwein, J. et al. (2007) Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 67, 427-432.
47. Papadopoulou, E. et al. (2006) Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. N. Y. Acad. Sci. 1075, 235-243.
48. Henrique, R. et al. (2005) Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol. 24, 264-269.
49. Aitchison, A. et al. (2007) RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 67, 638-644.
50. Dhillon, V.S. et al. (2004) Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin. Br. J. Cancer 90, 874-881.
51. Hong, F.Z. et al. (2005) Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas. Zhonghua Bing. Li Xue. Za Zhi. 34, 257-261.
52. Chan, M.W. et al. (2005) Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin. Cancer Res. 11, 7376-7383.
53. Wiley, A. et al. (2006) Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int. J. Gynecol. Cancer 16, 210-218.
54. Yang, H.J. et al. (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6, 212.
55. van'd., V. et al. (2003) Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int. J. Cancer 106, 472-479.
56. Mori, T. et al. (2006) Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 66, 6692-6698.
57. Maat, W. et al. (2007) Epigenetic inactivation of RASSF1a in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 48, 486-490.
58. House, M. G. et al. (2003) Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann. Surg. 238, 423-431.
59. Lee, S. et al. (2003) Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. J. Pathol. 163, 1371-1378.
60. Sugawara, W. et al. (2007) Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr. Blood Cancer 49, 240-249.
61. Wu, D.L. et al. (2006) Methylation in esophageal carcinogenesis. World J. Gastroenterol. 12, 6933-6940.
62. Esteller, M. (2003) Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin. Immunol. 109, 80-88.
63. Wilson, A.S. et al. (2007) DNA hypomethylation and human diseases. Biochim. Biophys. Acta 1775, 138-162.
64. Ehrlich, M. (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413.
65. Brock, M.V. et al. (2007) Cancer as a manifestation of aberrant chromatin structure. Cancer J. 13, 3-8.
66. Nan, X. et al. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386-389.
67. Kondo, Y. et al. (2007) Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res..
68. Vincent, A. et al. (2007) Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene.
69. Zhang, Y. et al. (1999) Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13, 1924-1935.
70. Harikrishnan, K.N. et al. (2005) Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat. Genet. 37, 254-264.
71. Jirtle, R.L. and Skinner, M.K. (2007) Environmental epigenomics and disease susceptibility. Nat. Rev. Genet. 8, 253-262.
72. Falls, J.G. et al. (1999) Genomic imprinting: implications for human disease. Am. J. Pathol. 154, 635-647.
73. Weidman, J.R. et al. (2007) Cancer susceptibility: epigenetic manifestation of environmental exposures. Cancer J. 13, 9-16.
74. Rakyan, V.K. et al. (2002) Metastable epialleles in mammals. Trends Genet. 18, 348-351.